These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy. See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366 [TBL] [Abstract][Full Text] [Related]
30. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Baughan T; Shababi M; Coady TH; Dickson AM; Tullis GE; Lorson CL Mol Ther; 2006 Jul; 14(1):54-62. PubMed ID: 16580882 [TBL] [Abstract][Full Text] [Related]
31. HnRNP C1/C2 may regulate exon 7 splicing in the spinal muscular atrophy gene SMN1. Irimura S; Kitamura K; Kato N; Saiki K; Takeuchi A; Gunadi ; Matsuo M; Nishio H; Lee MJ Kobe J Med Sci; 2009 Mar; 54(5):E227-36. PubMed ID: 19628962 [TBL] [Abstract][Full Text] [Related]
32. Spinal muscular atrophy: state-of-the-art and therapeutic perspectives. Wirth B Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):87-95. PubMed ID: 12215230 [TBL] [Abstract][Full Text] [Related]
33. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Kashima T; Manley JL Nat Genet; 2003 Aug; 34(4):460-3. PubMed ID: 12833158 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Thurmond J; Butchbach ME; Palomo M; Pease B; Rao M; Bedell L; Keyvan M; Pai G; Mishra R; Haraldsson M; Andresson T; Bragason G; Thosteinsdottir M; Bjornsson JM; Coovert DD; Burghes AH; Gurney ME; Singh J J Med Chem; 2008 Feb; 51(3):449-69. PubMed ID: 18205293 [TBL] [Abstract][Full Text] [Related]
35. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. Tisdale S; Pellizzoni L J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904 [TBL] [Abstract][Full Text] [Related]
36. The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. d'Ydewalle C; Ramos DM; Pyles NJ; Ng SY; Gorz M; Pilato CM; Ling K; Kong L; Ward AJ; Rubin LL; Rigo F; Bennett CF; Sumner CJ Neuron; 2017 Jan; 93(1):66-79. PubMed ID: 28017471 [TBL] [Abstract][Full Text] [Related]
37. The effect of the DcpS inhibitor D156844 on the protective action of follistatin in mice with spinal muscular atrophy. Harris AW; Butchbach ME Neuromuscul Disord; 2015 Sep; 25(9):699-705. PubMed ID: 26055638 [TBL] [Abstract][Full Text] [Related]
38. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Coady TH; Shababi M; Tullis GE; Lorson CL Mol Ther; 2007 Aug; 15(8):1471-8. PubMed ID: 17551501 [TBL] [Abstract][Full Text] [Related]
40. High expression level of Tra2-β1 is responsible for increased SMN2 exon 7 inclusion in the testis of SMA mice. Chen YC; Chang JG; Jong YJ; Liu TY; Yuo CY PLoS One; 2015; 10(3):e0120721. PubMed ID: 25781985 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]